Roar Adelsten
Owns 64.4% (privately and via companies). Founder and business developer within the Auxesis group since 2014.
For investors
Welcome to Auxesis Pharma’s investor pages. Here you will find financial information, press releases, and details on how you can invest in the company.
2016
Founded
800
Shareholders
1(+3)
Patents
82
Share price (SEK)
Why invest?
Auxesis Pharma is currently conducting a new share issue to accelerate our growth and expansion into new markets.
As an investor, you have the opportunity to join the journey as we transform the treatment of skin pain globally.
Global market potential
Skin pain and irritation category (OTC human)
- The global dermal pain relief market is expected to reach USD 12.2 billion by 2027, with a 5.2% CAGR (2020–2027).
- North America and Europe account for 68% of the global market.
- Asia-Pacific is expected to have the strongest growth rate during 2020–2027 with a 6.5% CAGR.
* The chart illustrates regional market share (example data).
A solid ownership structure
Other owners
Other owners collectively hold 35.6% and are primarily private individuals and small companies.
Shareholders
Auxesis has approximately 800 shareholders. The source for holdings is Euroclear Sweden, which maintains the share register. Figures as of 2025-12-31.
Management team
Experienced leaders with deep expertise in medtech, pharmaceuticals, and business development
Peter Åberg
CEO, Drug Development & Sustainability
Peter Åberg leads Auxesis’ strategic development with strong expertise in medtech and pharmaceuticals.
Expertise and background
- •CEO and Sustainability Director in medtech
- •Toxicology and drug safety
- •International leadership experience
Contribution: Drives Auxesis strategically toward sustainable global growth.
Roar Adelsten
Founder and Board Member
Visionary founder with nearly 30 years of experience in the pharmaceutical industry.
Expertise and background
- •Pfizer AS – medical consultant
- •International experience
- •Product development in orthopedics
Contribution: Ensures long-term strategy and innovation.
Lars Larsson
Finance & Strategy
Lars Larsson is responsible for Auxesis’ finance and financial strategy. With extensive experience in financial governance and business development, he supports the company’s stability and growth.
Expertise and background
- •Extensive experience in financial leadership and governance
- •Specialist in strategic financial planning and budgeting
- •Expertise in investor relations and capital markets
- •Experience from finance functions within the life sciences sector
Contribution: Ensures financial stability and drives growth that enables Auxesis’ continued expansion and innovation.
A strong board and management team
Auxesis Pharma has a well-composed board and management team representing a broad set of competencies
Auxesis Pharma Board
Roar Adelsten
Deputy CEO and Board Member
Magnus Larsson
Chairman of the Board
Rune Nordström
Board Member
Charlotta Larsson
Board Member
Auxesis Pharma Management Team
Peter Åberg
CEO, Drug Development & Sustainability
Roar Adelsten
Deputy CEO
Lars Larsson
Finance & Strategy
Financial calendar
Key dates for financial reports, annual general meetings, and other investor-related events.
Upcoming events
Ongoing offering
The ongoing offering can be subscribed to until 2026-02-13.
Upcoming offering
The upcoming offering can be subscribed to from 2026-02-14.
Annual General Meeting 2026
Publication of the AGM for the 2026 financial year.
Financial reports
Annual report 2024
June 2025
Annual report 2023
June 2023
Contact IR
Do you have questions about the company or want to book a meeting with our IR contact?
Investor Relations
+46 (0)8-771 43 00